Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy (Podcast)

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy (Podcast) Clinical outcomes of natalizumab- associated progressive multifocal leukoencephalopathy P. Vermersch, MD, PhD ABSTRACT L. Kappos, MD Objective: Natalizumab, a therapy for multiple sclerosis (MS), has been associated with progres- R. Gold, MD sive multifocal leukoencephalopathy (PML), a rare opportunistic infection of the CNS associated J.F. Foley, MD with the JC virus. We assessed clinical outcomes and identified variables associated with survival T. Olsson, MD, PhD in 35 patients with natalizumab-associated PML. D. Cadavid, MD Methods: Physicians provided Karnofsky scores and narrative descriptions of clinical status. Data C. Bozic, MD were supplemented by the natalizumab global safety database. S. Richman, MD, MPH Results: At the time of analysis, 25 patients (71%) had survived. Survivors were younger (median 40 vs 54 years) and had lower pre-PML Expanded Disability Status Scale scores (median 3.5 vs 5.5) and a shorter time from symptom onset to diagnosis (mean 44 vs 63 days) compared with Address correspondence and reprint requests to Dr. Sandra individuals with fatal cases. Of patients with nonfatal cases, 86% had unilobar or multilobar Richman, Biogen Idec, Inc., 14 disease on brain MRI at diagnosis, whereas 70% of those with fatal cases had widespread dis- Cambridge Center, Cambridge, ease. Gender, MS duration, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Neurology Wolters Kluwer Health

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy (Podcast)

Richman, S.
Neurology , Volume 76 (20) – May 1, 2011
Download PDF
8 pages

Loading next page...
 
/lp/wolters-kluwer-health/clinical-outcomes-of-natalizumab-associated-progressive-multifocal-22iGbEm6Y9

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0028-3878
eISSN
1526-632X
DOI
10.1212/WNL.0b013e31821a446b
pmid
21576685
Publisher site
See Article on Publisher Site

Abstract

Clinical outcomes of natalizumab- associated progressive multifocal leukoencephalopathy P. Vermersch, MD, PhD ABSTRACT L. Kappos, MD Objective: Natalizumab, a therapy for multiple sclerosis (MS), has been associated with progres- R. Gold, MD sive multifocal leukoencephalopathy (PML), a rare opportunistic infection of the CNS associated J.F. Foley, MD with the JC virus. We assessed clinical outcomes and identified variables associated with survival T. Olsson, MD, PhD in 35 patients with natalizumab-associated PML. D. Cadavid, MD Methods: Physicians provided Karnofsky scores and narrative descriptions of clinical status. Data C. Bozic, MD were supplemented by the natalizumab global safety database. S. Richman, MD, MPH Results: At the time of analysis, 25 patients (71%) had survived. Survivors were younger (median 40 vs 54 years) and had lower pre-PML Expanded Disability Status Scale scores (median 3.5 vs 5.5) and a shorter time from symptom onset to diagnosis (mean 44 vs 63 days) compared with Address correspondence and reprint requests to Dr. Sandra individuals with fatal cases. Of patients with nonfatal cases, 86% had unilobar or multilobar Richman, Biogen Idec, Inc., 14 disease on brain MRI at diagnosis, whereas 70% of those with fatal cases had widespread dis- Cambridge Center, Cambridge, ease. Gender, MS duration,

Journal

Neurology – Wolters Kluwer Health

Published: May 1, 2011

There are no references for this article.